WO2026103775 - BENZAMIDE DERIVATIVE, AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/103775
Publication Date
21.05.2026
International Application No.
PCT/CN2025/134560
International Filing Date
13.11.2025
Title **
[English]
BENZAMIDE DERIVATIVE, AND USE THEREOF
[French]
DÉRIVÉ DE BENZAMIDE ET SON UTILISATION
[Chinese]
一种苯甲酰胺类衍生物及其用途
Applicants **
SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.
Inventors
LU, Xianping
PAN, Desi
LIU, Gang
Priority Data
202411640971.2
15.11.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1575 | |
| EPO | Filing, Examination, Granting | 11629 | |
| Japan | Filing, Examination, Granting | 2016 | |
| South Korea | Filing, Examination, Granting | 1794 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,754
Contact Us
Abstract[English]
Provided in the present invention are a benzamide derivative and the use thereof. The described benzamide derivative is shown as formula (I), and can be used as a histone deacetylase inhibitor (HDACi) to treat tumors or hyperproliferative diseases.[French]
La présente invention concerne un dérivé de benzamide et son utilisation. Le dérivé de benzamide décrit est représenté par la formule (I), et peut être utilisé en tant qu'inhibiteur d'histone désacétylase (HDACi) pour traiter des tumeurs ou des maladies hyperprolifératives.[Chinese]
本发明提供了一种苯甲酰胺类衍生物及其用途。前述苯甲酰胺类衍生物如式(I)所示，其可作为组蛋白去乙酰化酶抑制剂(HDACi)治疗肿瘤或过度增殖类疾病。